Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Enanta Pharmaceuticals (ENTA) EPS (Weighted Average and Diluted) (2016 - 2025)

Enanta Pharmaceuticals' EPS (Weighted Average and Diluted) history spans 14 years, with the latest figure at -$0.42 for Q4 2025.

  • For Q4 2025, EPS (Weighted Average and Diluted) rose 60.0% year-over-year to -$0.42; the TTM value through Dec 2025 reached -$3.21, up 35.15%, while the annual FY2025 figure was -$3.84, 29.93% up from the prior year.
  • EPS (Weighted Average and Diluted) reached -$0.42 in Q4 2025 per ENTA's latest filing, up from -$0.88 in the prior quarter.
  • In the past five years, EPS (Weighted Average and Diluted) ranged from a high of -$0.42 in Q4 2025 to a low of -$1.86 in Q2 2023.
  • Average EPS (Weighted Average and Diluted) over 5 years is -$1.28, with a median of -$1.3 recorded in 2022.
  • Peak YoY movement for EPS (Weighted Average and Diluted): plummeted 263.33% in 2021, then soared 60.0% in 2025.
  • A 5-year view of EPS (Weighted Average and Diluted) shows it stood at -$1.48 in 2021, then increased by 6.08% to -$1.39 in 2022, then fell by 13.67% to -$1.58 in 2023, then skyrocketed by 33.54% to -$1.05 in 2024, then skyrocketed by 60.0% to -$0.42 in 2025.
  • Per Business Quant, the three most recent readings for ENTA's EPS (Weighted Average and Diluted) are -$0.42 (Q4 2025), -$0.88 (Q3 2025), and -$0.85 (Q2 2025).